Prescription Drug Prices Fall 3.1% Year-Over-Year in July, Steepest Decline in Over 60 Years
核心洞察
The Bureau of Labor Statistics reported year-over-year prescription drug prices fell 3.1% in July, the steepest decline in over 60 years.
The White House attributes the drop to new drug company pricing agreements and the launch of TrumpRX, a direct-to-consumer purchasing site.
Experts caution the figures measure out-of-pocket costs, not manufacturer prices, which actually ticked up last month.
Prescription drug prices fell 3.1% year-over-year in July compared to a year ago, according to the latest figures from the Bureau of Labor Statistics, marking the steepest decline in over 60 years. The data, buried within the monthly price breakdown, prompted President Donald Trump to claim credit for the drop, holding up a printed news headline during remarks to reporters at Joint Base Andrews on Friday.
"Prescription prices are down," Trump told reporters. "Is anyone impressed? You are!"
The White House credits two main policies for the decline: new agreements between the White House and drug companies to provide some prescriptions at lower prices, and the launch of TrumpRX, a direct-to-consumer site where people can purchase certain drugs.
A More Complicated Picture
Health policy experts offered a more nuanced assessment of the figures. "I would say it's a little bit complicated," said Cynthia Cox of KFF (搜索), a nonpartisan health policy research organization.
Cox noted that the Trump administration deserves some credit, but that many other factors are also at play. Among them, the Inflation Reduction Act signed by former President Joe Biden in 2022 has policies just taking effect this year that allow the government to negotiate lower prices for certain high-priced prescriptions used by Medicare recipients. She also pointed to a significant price drop for the popular weight-loss drugs known as GLP-1s.
"It's probably one of those all-of-the-above kind of situations where it's a combination of both Republican policies, Democrat policies from the Biden administration era and also market pressure," Cox said.
An Important Caveat on What the Numbers Measure
Richard Frank, a senior fellow in economic studies and director of the Center on Health Policy at the Brookings Institution (搜索), emphasized a critical distinction in interpreting the data. "I don't want to poo-poo it all," Frank said, while adding an important caveat: the numbers measure out-of-pocket costs for prescriptions, which are down, but the amount drug manufacturers are receiving actually ticked up last month.
That dynamic, Frank explained, means insurance companies are likely absorbing the difference and will seek to pass those costs on to consumers through higher premiums down the road.
"The really important thing here is to not interpret this as if manufactured drug prices are falling," Frank said.